Home Use Opportunity Target the expanding home-based neuromodulation market by positioning NEST as a safer, lower-cost, patient-friendly alternative to in-clinic TMS, appealing to patients with treatment-resistant depression seeking convenience and reduced clinic visits.

Clinical Validation Leverage the positive safety and tolerability profile and the completed 200-patient trial to pursue partnerships with academic medical centers and private psychiatry practices, highlighting potential for faster regulatory clearance and broader payer acceptance.

Regulatory Path Highlight the ongoing 510K submission strategy to gain FDA clearance for home use, presenting a clear pathway to scale commercialization and open up large addressable market segments in the US and international markets with similar regulatory frameworks.

Market Positioning Differentiate from conventional TMS by emphasizing personalization to individual EEG alpha frequency, which can be used in sales pitches to clinics and hospital networks seeking advanced, tailored neuromodulation therapies with potentially better outcomes.

Funding Momentum Capitalize on past Series D and equity financing signals to approach strategic investors, venture funds, and pharma-related collaborators for co-development, distribution agreements, or joint ventures to accelerate commercialization and scale.